Al's Comment:

We have covered Onc201 extensively in past News Blasts. The Musella Foundation has been fighting for years to get patient access to this drug, as we know it can help patients with diffuse midline glioma (DMG) with the H3K27 mutation. We have funded $875,000 in grants to help develop this treatment (we were not mentioned in the article because we did not fund this specific project).  Now that results showing Onc201 nearly doubles median survival for DMG-H3K27 patients have been published in a peer-reviewed journal, there will be a wave of news coverage for this drug. But the important part of this story is that patients STILL cannot easily access this drug.  This is not right, and it is a clear example of why we need the Promising Pathway Act. If you haven't already, please click here to send a letter to your Congress reps in support of the Act.

Posted on: 08/18/2023

Scientists Find New Weapon Against Brain Tumor: 'Major Crack in the Armor'


Click HERE to return to brain tumor news headlines.

Our privacy / cookie policy has changed.
Click HERE to read it!